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Um método alternativo por eletroforese capilar de zona (CZE) para determinação de 
ciprofloxacina (CPFLX), gatifloxacina (GTFLX), moxifloxacina (MFLX) e ofloxacina (OFLX) 
foi validado. O sistema de eletrólito utilizado consistiu da mistura de 25 mmol L-1 de TRIS/ HCl 
e 15 mmol L-1 de tetraborato de sódio em meio aquoso resultando em pH 8,87. A análise foi 
realizada sob detecção direta por UV em 282 nm com tempo de análise de 3 min. Os parâmetros 
analíticos de validação avaliados foram: linearidade (r > 0,998), seletividade (comparação entre 
a inclinação da curva de calibração de padronização externa e curva de calibração de adição de 
padrão), repetitividade em área para amostras (RSD %: < 3,94% para CPFLX, < 3,87% para 
GTFLX, 1,30% para MFLX e < 1,88% para OFLX), precisão intermediária em área para amostras 
(RSD%: < 3,59% para CPFLX, < 3,09% para GTFLX, 2,67% para MFLX e < 2,25% para OFLX), 
exatidão (média da faixa de recuperação: 101,2% para CPFLX, 101,0% para GTFLX, 101,3% para 
MFLX e 99,9% para OFLX), limite de detecção (mg L-1: 2,72 para CPFLX, 1,92 para GTFLX, 
0,795 para MFLX e 1,05 para OFLX), limite de quantificação (mg L-1: 9,06 para CPFLX, 6,40 
para GTFLX, 2,65 para MFLX e 3,50 para OFLX) e robustez. Devido à simplicidade, seletividade, 
precisão, exatidão e rapidez, o método pode ser uma alternativa interessante para auxiliar o controle 
da qualidade dessas drogas na indústria farmacêutica. 
An alternative capillary zone electrophoresis (CZE) method for the determination of 
ciprofloxacin (CPFLX), gatifloxacin (GTFLX), moxifloxacin (MFLX) and ofloxacin (OFLX) 
through a simple aqueous electrolyte system consisting of 25 mmol L-1 of TRIS/ hydrochloride and 
15 mmol L-1 of sodium tetraborate buffer mixture (pH 8.87) using direct UV detection at 282 nm 
within 3 min was validated. The analytical parameters of validation evaluated were: linearity  
(r > 0.998), selectivity (comparison between slope of the calibration curve of external standard 
and calibration curve of standard addition), repeatability in area for sample (RSD%: < 3.94% 
for CPFLX, < 3.87% for GTFLX, 1.30% for MFLX and < 1.88% for OFLX), intermediate 
precision in area for sample (RSD%: < 3.59% for CPFLX, < 3.09% for GTFLX, 2.67% for MFLX  
and < 2.25% for OFLX), accuracy (mean of recovery range: 101.2% for CPFLX, 101.0% for 
GTFLX, 101.3% for MFLX and 99.9% for OFLX), limit of detection (mg L-1: 2.72 for CPFLX, 
1.92 for GTFLX, 0.795 for MFLX and 1.05 for OFLX), limit of quantification (mg L-1: 9.06 for 
CPFLX, 6.40 for GTFLX, 2.65 for MFLX and 3.50 for OFLX) and robustness. Due to its simplicity, 
selectivity, precision, accuracy and rapidity, the methodology can be an interesting alternative for 
quality assurance in the pharmaceutical industry of these drugs.
Keywords: capillary zone electrophoresis, fluoroquinolones, validation, pharmaceutical 
formulations
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Introduction
Fluoroquinolones (FQs) comprise a group of antibiotics 
with a broad spectrum of activity and good tolerance, being 
used in the treatment of a variety of bacterial infections 
in human and veterinary medicine. They are effective 
against Gram-positive, Gram-negative and micobacterial 
organisms as well as anaerobes. The bactericidal activity 
generated by FQs is caused by their inhibition of two 
bacterial enzymes: DNA gyrase and topoisomerase IV 
enzymes. In accordance with World Health Organization 
(WHO), this class of antibiotics is considered the first-
line therapy for complicated urinary tract and bacterial 
diarrhea and second-line for the treatment of tuberculosis 
in patients with resistance or intolerance to first line anti-
tuberculosis therapy. They are also alternative agents for 
the treatment of many sexually transmitted diseases, as 
well as osteomyelitis, some cases of wound infection and 
selected respiratory infections.1
Quality control analyses in the pharmaceutical industry 
involve the determination of multiple parameters for both 
raw materials and end products. The analytical techniques 
that have been used in quality control analyses of FQs 
in pharmaceutical products are high performance liquid 
chromatography (HPLC),2-5 UV spectrophotometry 6 and 
titrimetry.7
Within the context of capillary electrophoresis (CE), 
some methodologies have been described for FQs analysis 
in pharmaceutical formulations. Sun and Chen8 carried out 
methodological optimization for the determination of 14 
quinolones and FQs in pharmaceuticals at about 8.0 min by 
using a complex electrolyte system consisting of sodium 
borate/ sodium dihydrogenphosphate/ sodium cholate/ 
sodium heptanesulfonate/ acetonitrile. The separation 
was established using the overlapping resolution mapping 
scheme. After that, Sun and Wu,9 achieved the separa-
tion of 7 FQs using sodium borate/ sodium dihydrogen 
phosphate/ sodium cholate/ acetonitrile within 8.5 min 
of electrolyte running. Finally, Fierens et al.10 performed 
partial separation of 10 quinolones and FQs at about 14 min 
using sodium phosphate buffer (pH ≈ 7). Additionally, the 
reviews published by Flurer describing recent advances in 
the analysis of antibiotics by CE, among which the FQs, 
presented an overview about the determination of this kind 
of pharmaceutical in different matrixes.11-13 
Due to the use of FQs for human infections and pro-
phylactic treatment of some animal species used in food 
industry, the development and validation of methodology 
capable of improving the quality control of pharmaceutical 
formulations used for this purpose is very important. 
Within this context, this work describes a thorough 
validation of the CZE method for the determination of 
ciprofloxacin, (CPFLX), gatifloxacin (GTLFX), moxi-
floxacin (MFLX) and ofloxacin (OFLX) in pharmaceutical 
formulations by using sparfloxacin (SPFLX) as internal 
standard - IS (Figure 1). This methodology, in comparison 
with others previously described in the literature for the 
analysis of FQs pharmaceutical formulations, presents the 
Figure 1. Chemical structure of the fluoroquinolones studied.
Table 1. Excipients present in the FQs tablets
Pharmaceutical Formulation Excipients
CPFLX starch, microcrystalline cellulose, crospovidone, silicion dioxide, titanium dioxide, magnesium stearate, HPM cel-
lulose and macrogol
GTFLX sorbic acid, microcrystalline cellulose, titanium dioxide, magnesium stearate, sodium starch glycolate, hydroxypropyl 
methylcellulose, methylcellulose, poliethylenoglycol, polysorbate 80 and simethicone
MFLX microcrystalline cellulose, titanium dioxide, magnesium stearate, hypromellose, lactose, macrogol and ferric oxide
OFLX starch, carboxymethylcellulose, titanium dioxide, magnesium stearate, sodium starch glycolate, hydroxypropyl 
methylcellulose, lactose, ferric oxide and poliethylenoglycol
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analysis of more recent FQs such as GTLFX and MFLX, 
shorter analysis time and simpler reagents in the back-
ground electrolyte.8-10 Table 1 shows the excipients present 
in each tablet analyzed. The presence of these makes the 
use of a selective method necessary. 
Experimental
Reagents and solutions
All reagents were of analytical grade and solvents 
were of chromatography purity. TRIS (2-amino-2- 
(hydroxymethyl)-1,3-propanodiol) was obtained from 
Pharmacia Biotech (Uppsala, Sweden) and sodium tetra-
borate was obtained from Vetec (Rio de Janeiro, Brazil). 
Electrolyte solutions consisted of buffer mixture containing 
25 mmol L-1 TRIS/ hydrochloride and 15 mmol L-1 sodium 
tetraborate and were prepared fresh daily. The FQs standard 
CPFLX, GTFLX, MFLX, SPFLX and OFLX were obtained 
from Xiamen Mchem Pharma group (Xiamen, China).
Standard solution
Stock solutions containing 20.0 mg of each FQs (CP-
FLX, GTFLX, MFLX and OFLX) and SPFLX (IS) were 
separately dissolved in 25.0 mL methanol and stored in a 
freezer. These solutions, after adequate dilution, were used 
for the validation study.
Sample solutions
For each FQ formulation, seven tablets were individually 
weighed and ground to homogeneously fine powders. 
The powder corresponding to 10.0 mg active ingredient 
of CPFLX, GTFLX MFLX and OFLX and 5.0 mg of 
IS was weighed and dissolved in 25.0 mL of methanol 
in a volumetric flask. After sonication for 10 min, the 
suspensions were filtered through a 0.45 µm Millipore 
filter (São Paulo, Brazil) to obtain clear solutions that were 
adequately diluted before injection.
Instrumentation
All experiments were performed in a capillary 
electrophoresis system (model HP3d CE, Agilent 
Technologies, Palo Alto, USA) equipped with a diode 
array detector set at 282 nm, a temperature control device 
maintained at 25 ºC and an acquisition and treatment data 
software (HP ChemStation, rev A.06.01). Samples were 
hydrodynamically injected (30 mbar for 5s and 50 mbar 
for 10s) and the electrophoretic system was operated under 
normal polarity and constant voltage conditions of +25 kV. 
Fused-silica capillaries (Polymicro Technologies, Phoenix, 
AZ, USA) 48.5 cm (40 cm effective length) x 50 µm I.D. 
and 75 µm x 375 µm O.D. were used.
Analytical procedures
When a new capillary was used, it was conditioned by a 
pressure flush of 1.0 mol L-1 NaOH solutions (30 min), de-
ionized water (5 min) and electrolyte solution (10 min). In 
between runs, the capillary was replenished with 0.2 mol L-1 
NaOH solutions (2 min), deionized water (2 min) and fresh 
electrolyte solution (3 min, pressure flush). 
Results and Discussion
Applied separation method 
The methodology applied to the present work was 
developed by Faria et al.14 using 25 mmol L-1 of TRIS/ 
hydrochloride and 15 mmol L-1 of sodium tetraborate 
buffer mixture (pH 8.87) as electrolyte system. In this 
previous paper the study of a set of experiments was 
carried out considering FQs effective mobility curve versus 
pH to optimize the electrolyte system composition. The 
quantitative measurement for the separation performance 
equation (QMSP) was used to select the optimum 
separation, taking into account the total sum of the 
resolution of the adjacent pair peaks, migration time of 
the last peak, resulting pH and resulting ionic strength 
simultaneously. Figure 2 shows the characteristic profile 
of separation under optimum conditions.
System suitability 
Before the beginning of the validation experiments, the 
system used for analysis must be evaluated to provide data 
of acceptable quality. Therefore, it is necessary to perform 
system suitability tests.15 The system suitability considers 
overall systems, including electrophoretic system and the 
calibration and maintenance of the equipments used. In this 
work, the system suitability was obtained by means of ten 
consecutive injections of standard mixture using internal 
standard through relative standard deviation (RSD) to 
repeatability in area and migration time and the adjacent 
pair peaks resolution (R
S
) calculated by equation 1 
(Table 2).16 In the present case, R
A,B










 the peak width measured at the base. 
The RSD was lower than 1.00 % up to ten repetitions in 
area and migration time and the resolution was higher than 
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1.50 for all adjacent pair peaks. Therefore, the system was 
suitable for carrying out the validation procedure.
 (1)
Validation procedures
In order to significantly reduce the injection-related 
imprecision and to ensure better reproducibility and greater 
control over the sample amount injected, the use of an 
internal standard in the quantitative analysis is generally 
preferred.17 Therefore, it’s important to stress the use of SP-
FLX as IS during all validation procedures in this work. 
Selectivity and linearity 
Due to the difficulty in obtaining a matrix free of the 
active ingredient, it was necessary to use the method of 
standard addition to evaluate the method selectivity. Therefore, 
calibration curves for the method of standard additions and 
calibration curves for the method of external standard were 
compared.18 The similarity in the slopes presented between 
calibration curves (Table 3) indicates that the method presented 
appropriate selectivity for FQ analysis. 
Linearity was evaluated taking into account the 
correlation coefficient (r). The correlation coefficient equal 
to or higher than 0.999 is considered evidence of ideal data 
fitting to line regression performed through least-square 
treatment.19
Another way to verify the linearity could be through 
the application of the linearity hypothesis test a priori.20 
This test consists of comparing the deviations of the means 
from the calibration line (the residual standard deviation 
(s
yx
) with that of the y values from their means (s
y
) by using 
equation 2, where m
i
 is the number of measurement, p is the 




The test is carried out by the comparison between F
calculated
 and 
Fα; f1= p-2; f2=m-p (Fcritical). If Fcalculated ≥ Fcritical, the linear model 
cannot be applied.
 
In this case, the F
critical
 value, that is, 
F 
0,05; 3; 10 
is equal to 3.71. Therefore, null hypothesis was not 
rejected, indicating that the linearity test was considered to 
be satisfactory, as summarized in Table 3. As a result, the 
method was found selective and its linearity was considered 
to be suitable in the concentration range studied.
Precision
Precision can be determined through the estimate of 
the relative standard deviation (RSD).19 The precision in 
the validation of this optimized method was performed in 
two levels: repeatability and intermediate precision. The 
repeatability of the method was obtained through evaluation 
of the RSD by measuring run-to-run for migration time 
ratios and peak area ratios using internal standard for three 
different standard preparations and seven different tablets 
of each FQ (Tables 4 and 5).
As it can be seen from Table 4, the RSD of the areas was lower 
than 1.00 % for all FQs standards and the highest RSD for the 









MFLX1 0.943 0.0336 1.56 R
1,2
GTFLX2 0.810 0.0258 1.87 R
2,3
SPFLX3 0.640 0.0205 6.11 R
3,4
CPFLX4 0.641 0.0205 2.20 R
4,5
OFLX5 0.682 0.0250
Figure 2. Simultaneous determination of standard mixture containing 
MFLX, GTFLX, SPFLX (IS), CPFLX and OFLX each 100.0 mg L-1. 
Electrolyte composition: 25 mmol L-1 TRIS/ hydrochloride and 15 mmol 
L-1 sodium tetraborate buffer mixture. Other conditions: 5s injection at 
30 mbar pressure, +25 kV applied voltage, 25 ºC cartridge temperature, 
direct detection at 282 nm and capillary 48.5 cm (40 cm effective length) 
× 50 µm I.D.
393Faria et al.Vol. 19, No. 3, 2008
samples was 3.94 % (Table 5). The dispersion among results in the 
sample includes factors such as matrix effect, tablet mass variation 
and variations in the sample preparation. For migration time, all 
the results were lower than 1.00 % for standards and samples. 
Therefore, the results were considered acceptable.
The intermediate precision of the method was obtained 
through evaluation of the RSD by measuring day-to-day 
migration time ratios and peak area ratios using internal 
standard seven different tablets of each FQ. The evaluation 
of the analysis for intermediate precision was performed 
twelve days after the first analysis. The results shown in Table 
6 reveal that the highest value for the area was 3.59 % and 
for migration time it was lower than 1.00 %. These values are 
considered to be acceptable, since the calculations were based 
on the analysis of each tablet in independent preparations. This 
type of procedure simultaneously evaluates the precision of 
this method and the analytical concentration dispersion of the 
active ingredients in the tablets.
Accuracy
Accuracy represents the level of compliance between 
individual results obtained and a reference value. In this 
work, accuracy was obtained through recovery.19 
In order to calculate the recovery percentage (R%), 
standard injections of samples spiked in the range of 25.0 
to 125.0 mg L-1 were carried out, and equation 3, where A
a
 
is the analyte area, A
s
 is the standard area and A
a+s
 is the 
analyte area with standard addition was used.
 (3)
Table 7 shows the recovery results for all the samples 
within the range of 95 to 105% obtained for the tablets 
analyzed.
Table 3. Statistical results obtained from linearity calculation
FQs Slope Intercept r F
calculated 
CPFLXa 0.209 ± 0.003 -0.02 ± 0.02 0.999 3.30
CPFLXb 0.217 ± 0.005 10.9 ± 0.4 0.999
GTFLXa 0.034 ± 0.001 -0.06 ± 0.06 0.999 3.17
GTFLXb 0.034 ± 0.001 1.62 ± 0.05 0.999
MFLXa 0.036 ± 0.001 -0.14 ± 0.08 0.998 3.03
MFLXb 0.036 ± 0.001 1.79 ± 0.06 0.999
OFLXa 0.061 ± 0.001 -0.07 ± 0.05 0.999 3.23
OFLXb 0.062 ± 0.001 3.11 ± 0.06 0.999
acalibration curve of external standard (n=3); bcalibration curve of standard additions (n=7).
Table 4. RSD (%) in area and in migration time for standards obtained from repeatability study
Concentration / (mg L-1)
CPFLX GTFLX MFLX OFLX
Peak Area Ratios / (RSD %)a
25.0 0.250 0.751 0.748 0.301
50.0 0.497 0.705 0.374 0.766
75.0 0.910 0.613 0.0523 0.332
100.0 0.408 0.173 0.203 0.327
125.0 0.392 0.435 0.621 0.305
Migration time Ratios / (RSD %)a
25.0 0.101 0.245 0.0577 0.0208
50.0 0.0307 0.307 0.0152 0.0434
75.0 0.0174 0.184 0.0392 0.0265
100.0 0.0254 0.120 0.0514 0.0108
125.0 0.0243 0.272 0.0719 0.0296
an=3.
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Limit of detection (LOD) and limit of quantification 
(LOQ)
LOD and LOQ represent the lower concentration of 
the substance under evaluation that can be detected and 
measured using a certain experimental procedure. They 
can be calculated in three different ways: visual method, 
signal-noise relation and calibration curve parameter 
evaluation.19
In this work, the signal-noise relation through the 
standard deviation calculation of the baseline (noise) and 
the height of the peak (signal) of the analytes were used. 
Table 5. RSD (%) in area and in migration time for samples obtained from repeatability study
Standard concentration 
added / (mg L-1)
CPFLX GTFLX MFLX OFLX
Peak Area Ratios / (RSD %)a
0.0 3.57 3.87 1.30 1.88
25.0 2.06 2.11 0.961 1.06
50.0 2.91 1.77 1.31 0.881
75.0 3.94 0.391 1.76 0.453
100.0 2.78 1.87 0.736 1.69
125.0 1.73 0.666 1.22 0.885
Migration time Ratios / (RSD %)a
0.0 0.537 0.201 0.316 0.265
25.0 0.535 0.168 0.251 0.363
50.0 0.532 0.128 0.195 0.450
75.0 0.476 0.139 0.188 0.282
100.0 0.469 0.119 0.124 0.362
125.0 0.361 0.173 0.106 0.292
an=7 (independent preparation for each sample).
Table 6. RSD (%) in area and in migration time for samples obtained 
from intermediate precision
Concentration 
Added / (mg L-1)
Peak Area Ratiosa /
RSD (%)
Migration Time 














LOD and LOQ was calculated within the concentration 
corresponding to signal-noise relation equal to 3 (equation 
4) and 10 (equation 5) respectively, where S
b
 is the standard 
deviation of the baseline, C
S
 is the concentration of analyte, 
H
max 
is the maximum peak height and H
min
 is the baseline 
level. The limit of detection (mg L-1) was 2.72 for CPFLX, 
1.92 for GTFLX, 0.795 for MFLX and 1.05 for OFLX and 
the limit of quantification (mg L-1) was 9.06 for CPFLX, 
6.40 for GTFLX, 2.65 for MFLX and 3.50 for OFLX. 
 (4)
 (5)
In general, lower LOD and LOQ values are not necessary 
for pharmaceutical analysis. However, in the case of food, 
environment or biological matrixes, in which the FQs can be 
found in low quantity, the sensitivity improvement is important. 
In order to show that the methodology can be adjustable for 
analysis in lower concentrations, we carried out an injection 
of FQs standard mixture in concentration of 1.0 mg L-1 after 
changing the injection from 30 mbar for 5s to 50 mbar for 
10 s and the internal capillary diameter from 50 µm to 75 µm. 
Figure 3 shows the electropherogram obtained.
Robustness or ruggedness 
Robustness or ruggedness of an analytical procedure is 
the measure of its capacity to keep unaffected parameters 
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Table 7. Percentage of recovery for CPFLX, GTFLX, MFLX and 
OFLX
Concentration 
Added / (mg L-1)
Concentration 
Found / (mg L-1)a
Recovery / (%)
           CPFLX
22.6 71.3 ± 1.5 99.7
45.0 95.9 ± 2.8 98.5
67.7 115.1 ± 4.5 100.5
90.3 143.8 ± 3.9 105.0
112.9 161.7 ± 2.8 102.2
 101.2b
           GTFLX
25.6 73.2 ± 1.8 98.7
50.5 96.2 ± 1.9 102.8
75.3 121.7 ± 0.6 102.8
100.9 145.9 ± 2.7 100.3
125.8 176.1 ± 0.9 100.6
 101.0b
           MFLX
22.6 70.4 ± 0.7 101.6
45.9 92.8 ± 1.2 102.8
63.7 112.7 ± 1.9 101.1
91.9 141.3± 1.0 100.9
115.3 166.9 ± 2.0 100.2
 101.3b
           OFLX
24.9 73.8 ± 0.8 98.4
50.6 101.2 ± 0.9 100.1
76.3 126.0 ± 0.6 99.9
101.3 151.8 ± 2.6 99.8
126.9 178.4 ± 1.6 101.5
 99.9b
aMean ± s.d. (n=7); bmean of recovery range. 




1- Voltage / kv 23 25 27
2- Temperature / ºC 23 25 27
3- Buffer composition: TRIS/HCl and sodium Tetraborate / (mmol L-1) 23/13 25/15 27/17
4- wavelength / nm 280 ± 2 282 ± 2 284 ± 2
5- Injection / (mbar x s) 30 x 4 30 x 5 30 x 6
6- Sonication time / min 8 10 12
Figure 3. Simultaneous determination of standard mixture containing 
(1) MFLX, (2) GTFLX, (3) SPFLX, (4) CPFLX and (5) OFLX each 1.0 
mg L-1. Electrolyte composition: 25 mmol L-1 TRIS/ hydrochloride and 
15 mmol L-1 sodium tetraborate buffer mixture. Other conditions: 10s 
injection at 50 mbar pressure, +25 kV applied voltage, 25 ºC cartridge 
temperature, direct detection at 282 nm and capillary 48.5 cm (40 cm 
effective length) × 75 µm I.D.
and to provide an indication of its reliability during normal 
usage.19,21
The parameters selected to evaluate robustness were: 
electrolyte composition, injection, voltage, temperature, 
wavelength and sonication time in the sample preparation. 
If the changes in these experimental parameters remained 
within acceptable limits of selectivity, accuracy and 
precision, the method was considered to be robust.15 Table 8 
shows the experiments performed for robustness evaluation. 
The OFLX was chosen to evaluate robustness randomly. 
The experiments were performed in triplicate.
As it can be observed from Table 9, the r-values were higher 
than or equal to 0.997 and the recovery achieved remained within 
the interval of 100.00 ± 5.0 %. Test-t was carried out among three 
values of amount found and the reference concentration. No 
significant difference was found between experiments 1 and 2 in 
the 95% reliability interval, while for experiment 3 no significant 
difference occurred in the 99% reliability interval. Therefore, little 
variations in the voltage, temperature, electrolyte composition, 
wavelength, injection and sonication time of the sample 
were found for lower values in relation to the validated value 
(experiment 1). No significant changes occurred in the correlation 
coefficient, accuracy and precision. However, experimental 
variation for higher values in relation to the validated value 
J. Braz. Chem. Soc.396 Validation of a Capillary Zone Electrophoresis Method for the Determination of Ciprofloxacin
(experiment 3) showed significant error in the quantification of 
the compounds in the 95% reliability interval. 
Conclusions
All validation parameters of the method evaluated 
have obeyed the variation limits permitted by the control 
organs such as ICH, WHO, US-FDA and USP. Therefore, 
the validated method can be useful for quality assurance in 
the pharmaceutical industry of these formulations, which 
present simple electrolyte system, short analysis time, and 
simple sample preparation as advantages.
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Table 9. Robustness results 
Analytical parameters Experiments
1 2 3
Correlation coefficient / r 0.997 0.998 0.999
Recovery % 95.1 100.9 97.2
Sample 1 378.5 403.8 381.1
Sample 2 380.0 390.6 389.0
Sample 3 393.2 397.0 377.0
Amount found / mgb 383.9 ± 2.1 397.1 ± 1.6 382.3 ± 1.6
teste-t (p-value)a 0.075 0.530 0.038
a Reference concentration: 400 mg; b Mean of triplicate.
